{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:00:33Z","timestamp":1784858433608,"version":"3.55.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":100,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32322045"],"award-info":[{"award-number":["32322045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71843-9","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:34:25Z","timestamp":1776242065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac reprogramming via transient overexpression of P-glycoprotein alleviates doxorubicin-induced cardiotoxicity in mice and pigs"],"prefix":"10.1038","volume":"17","author":[{"given":"Yixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-8381","authenticated-orcid":false,"given":"Huifang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-4348","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-0864","authenticated-orcid":false,"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"71843_CR1","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/s41591-024-03110-7","volume":"30","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial. Nat. Med. 30, 2568\u20132575 (2024).","journal-title":"Nat. Med."},{"key":"71843_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41551-020-0573-2","volume":"4","author":"S Li","year":"2020","unstructured":"Li, S. et al. Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nat. Biomed. Eng. 4, 732\u2013742 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"71843_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm1341","volume":"12","author":"M Bentires-Alj","year":"2006","unstructured":"Bentires-Alj, M. et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med. 12, 114\u2013121 (2006).","journal-title":"Nat. Med."},{"key":"71843_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","volume":"3","author":"A Shahbandi","year":"2022","unstructured":"Shahbandi, A. et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat. Cancer 3, 1513\u20131533 (2022).","journal-title":"Nat. Cancer"},{"key":"71843_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","volume":"145","author":"T Magdy","year":"2022","unstructured":"Magdy, T. et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation 145, 279\u2013294 (2022).","journal-title":"Circulation"},{"key":"71843_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.113.003688","volume":"128","author":"T Force","year":"2013","unstructured":"Force, T. & Wang, Y. Mechanism-based engineering against anthracycline cardiotoxicity. Circulation 128, 98\u2013100 (2013).","journal-title":"Circulation"},{"key":"71843_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-022-00757-y","volume":"19","author":"GB Lim","year":"2022","unstructured":"Lim, G. B. Circular RNA prevents doxorubicin-induced cardiotoxicity. Nat. Rev. Cardiol. 19, 574 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"71843_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35503-y","volume":"13","author":"M Huo","year":"2022","unstructured":"Huo, M. et al. Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron. Nat. Commun. 13, 7778 (2022).","journal-title":"Nat. Commun."},{"key":"71843_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale, D. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131, 1981\u20131988 (2015).","journal-title":"Circulation"},{"key":"71843_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/CIRCULATIONAHA.121.058128","volume":"145","author":"V Lo Sardo","year":"2022","unstructured":"Lo Sardo, V. & Kamp, T. J. Preventing anthracycline-induced cardiotoxicity using functional genomics and human-induced pluripotent stem cell-derived cardiomyocytes. Circulation 145, 295\u2013298 (2022).","journal-title":"Circulation"},{"key":"71843_CR11","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.redox.2023.102625","volume":"60","author":"BM Pharoah","year":"2023","unstructured":"Pharoah, B. M. et al. Hydropersulfides (RSSH) attenuate doxorubicin-induced cardiotoxicity while boosting its anticancer action. Redox Biol. 60, 102625 (2023).","journal-title":"Redox Biol."},{"key":"71843_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/d41573-020-00050-y","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. Stemming the tide of drug resistance in cancer. Nat. Rev. Drug Discov. 19, 221\u2013223 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"71843_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1126\/science.321.5887.355","volume":"321","author":"L Roberts","year":"2008","unstructured":"Roberts, L. & Simpson, S. Drug resistance. Deadly defiance. Introduction to special issue. Science 321, 355 (2008).","journal-title":"Science"},{"key":"71843_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jhep.2016.08.006","volume":"65","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, J., Bert, F. & Nicolas-Chanoine, M. H. The challenges of multi-drug-resistance in hepatology. J. Hepatol. 65, 1043\u20131054 (2016).","journal-title":"J. Hepatol."},{"key":"71843_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/adma.201303123","volume":"26","author":"Q He","year":"2014","unstructured":"He, Q. & Shi, J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv. Mater. 26, 391\u2013411 (2014).","journal-title":"Adv. Mater."},{"key":"71843_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0169-409X(02)00006-6","volume":"54","author":"TR Stouch","year":"2002","unstructured":"Stouch, T. R. & Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 54, 315\u2013328 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"71843_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0169-409X(02)00171-0","volume":"55","author":"JH Lin","year":"2003","unstructured":"Lin, J. H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55, 53\u201381 (2003).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"71843_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1474-4422(13)70128-5","volume":"12","author":"JA French","year":"2013","unstructured":"French, J. A. P-glycoprotein expression and antiepileptic drug resistance. Lancet Neurol. 12, 732\u2013733 (2013).","journal-title":"Lancet Neurol."},{"key":"71843_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","volume":"54","author":"MF Fromm","year":"2002","unstructured":"Fromm, M. F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54, 1295\u20131310 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"71843_CR20","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.drup.2023.101007","volume":"71","author":"K Szeb\u00e9nyi","year":"2023","unstructured":"Szeb\u00e9nyi, K. et al. Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells. Drug Resist. Updat. 71, 101007 (2023).","journal-title":"Drug Resist. Updat."},{"key":"71843_CR21","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1021\/nn2013707","volume":"5","author":"XB Xiong","year":"2011","unstructured":"Xiong, X. B. & Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5, 5202\u20135213 (2011).","journal-title":"ACS Nano"},{"key":"71843_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2004-10-4126","volume":"107","author":"Y Tabe","year":"2006","unstructured":"Tabe, Y. et al. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107, 1546\u20131554 (2006).","journal-title":"Blood"},{"key":"71843_CR23","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1021\/nn500205b","volume":"8","author":"K Cohen","year":"2014","unstructured":"Cohen, K., Emmanuel, R., Kisin-Finfer, E., Shabat, D. & Peer, D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 8, 2183\u20132195 (2014).","journal-title":"ACS Nano"},{"key":"71843_CR24","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/gast.2002.33594","volume":"122","author":"M Wagner","year":"2002","unstructured":"Wagner, M. et al. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 122, 1898\u20131912 (2002).","journal-title":"Gastroenterology"},{"key":"71843_CR25","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/D1CS00617G","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828\u20133845 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"71843_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201805116","volume":"31","author":"AK Patel","year":"2019","unstructured":"Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, e1805116 (2019).","journal-title":"Adv. Mater."},{"key":"71843_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"71843_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"71843_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.fmre.2023.09.007","volume":"5","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Plant-derived nanovesicles: promising therapeutics and drug delivery nanoplatforms for brain disorders. Fundam. Res. 5, 830\u2013850 (2023).","journal-title":"Fundam. Res."},{"key":"71843_CR30","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen, C. L., Haanen, J. B., Met, \u00d6 & Svane, I. M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450\u2013e458 (2022).","journal-title":"Lancet Oncol."},{"key":"71843_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 7, 94 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"71843_CR32","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/d41591-022-00091-3","volume":"28","author":"T Carvalho","year":"2022","unstructured":"Carvalho, T. mRNA vaccines boost BioNTech\u2019s CAR T cell therapy. Nat. Med. 28, 1968\u20131969 (2022).","journal-title":"Nat. Med."},{"key":"71843_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"M Liu","year":"2024","unstructured":"Liu, M., Hu, S., Yan, N., Popowski, K. D. & Cheng, K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565\u2013575 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"71843_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"71843_CR35","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/s41591-021-01602-4","volume":"27","author":"L Morris","year":"2021","unstructured":"Morris, L. mRNA vaccines offer hope for HIV. Nat. Med. 27, 2082\u20132084 (2021).","journal-title":"Nat. Med."},{"key":"71843_CR36","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"71843_CR37","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"71843_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30878-4","volume":"13","author":"Z Fang","year":"2022","unstructured":"Fang, Z. et al. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nat. Commun. 13, 3250 (2022).","journal-title":"Nat. Commun."},{"key":"71843_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89931-9","volume":"11","author":"W Yin","year":"2021","unstructured":"Yin, W. et al. The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci. Rep. 11, 10791 (2021).","journal-title":"Sci. Rep."},{"key":"71843_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13402-016-0285-5","volume":"39","author":"Y-L Chen","year":"2016","unstructured":"Chen, Y.-L. et al. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Cell. Oncol. 39, 411\u2013433 (2016).","journal-title":"Cell. Oncol."},{"key":"71843_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"71843_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21739","volume":"41","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med. Res. Rev. 41, 525\u2013555 (2021).","journal-title":"Med. Res. Rev."},{"key":"71843_CR43","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky, E. K. et al. Cardiac disturbances during the administration of taxol. J. Clin. Oncol. 9, 1704\u20131712 (1991).","journal-title":"J. Clin. Oncol."},{"key":"71843_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00280-017-3384-8","volume":"80","author":"C Panis","year":"2017","unstructured":"Panis, C. et al. Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer. Cancer Chemoth. Pharm. 80, 469\u2013478 (2017).","journal-title":"Cancer Chemoth. Pharm."},{"key":"71843_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101029","volume":"26","author":"S Zhu","year":"2024","unstructured":"Zhu, S. et al. Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor. Mater. Today Bio 26, 101029 (2024).","journal-title":"Mater. Today Bio"},{"key":"71843_CR46","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1158\/1535-7163.MCT-15-0986","volume":"15","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. Mol. Cancer Ther. 15, 2282\u20132293 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"71843_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani, M. et al. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc. Toxicol. 22, 292\u2013310 (2022).","journal-title":"Cardiovasc. Toxicol."},{"key":"71843_CR48","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S. & Navik, U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother. 139, 111708 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"71843_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijcard.2012.01.081","volume":"164","author":"SJ Aldous","year":"2013","unstructured":"Aldous, S. J. Cardiac biomarkers in acute myocardial infarction. Int. J. Cardiol. 164, 282\u2013294 (2013).","journal-title":"Int. J. Cardiol."},{"key":"71843_CR50","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1021\/acsnano.3c00195","volume":"17","author":"Q Jiang","year":"2023","unstructured":"Jiang, Q. et al. Doxorubicin detoxification in healthy organs improves tolerability to high drug doses for enhanced antitumor therapy. ACS Nano 17, 7705\u20137720 (2023).","journal-title":"ACS Nano"},{"key":"71843_CR51","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.cmet.2021.08.014","volume":"33","author":"X-J Zhang","year":"2021","unstructured":"Zhang, X.-J. et al. Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. Cell Metab. 33, 2059\u20132075.e2010 (2021).","journal-title":"Cell Metab."},{"key":"71843_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw3172","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats. Sci. Transl. Med. 12, eaaw3172 (2020).","journal-title":"Sci. Transl. Med."},{"key":"71843_CR53","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1161\/CIRCULATIONAHA.117.030785","volume":"137","author":"L Gao","year":"2018","unstructured":"Gao, L. et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell\u2013derived cardiac cells improve recovery from myocardial infarction in swine. Circulation 137, 1712\u20131730 (2018).","journal-title":"Circulation"},{"key":"71843_CR54","doi-asserted-by":"publisher","first-page":"eabd5758","DOI":"10.1126\/scitranslmed.abd5758","volume":"13","author":"JK Lunney","year":"2021","unstructured":"Lunney, J. K. et al. Importance of the pig as a human biomedical model. Sci. Transl. Med. 13, eabd5758 (2021).","journal-title":"Sci. Transl. Med."},{"key":"71843_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3820591","volume":"2022","author":"C Meng","year":"2022","unstructured":"Meng, C. et al. Preparation and evaluation of animal models of cardiotoxicity in antineoplastic therapy. Oxid. Med. Cell. Longev. 2022, 3820591 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"71843_CR56","doi-asserted-by":"publisher","first-page":"11620","DOI":"10.3390\/app122211620","volume":"12","author":"P Lin","year":"2022","unstructured":"Lin, P. et al. MR imaging and electrophysiological features of doxorubicin-induced fibrosis: protocol development in a small preclinical pig study with histological validation. Appl. Sci. 12, 11620 (2022).","journal-title":"Appl. Sci."},{"key":"71843_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"71843_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202302686","volume":"36","author":"L Luo","year":"2024","unstructured":"Luo, L. et al. Pericardial delivery of SDF-1\u03b1 puerarin hydrogel promotes heart repair and electrical coupling. Adv. Mater. 36, e2302686 (2024).","journal-title":"Adv. Mater."},{"key":"71843_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21682-7","volume":"12","author":"D Zhu","year":"2021","unstructured":"Zhu, D. et al. Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair. Nat. Commun. 12, 1412 (2021).","journal-title":"Nat. Commun."},{"key":"71843_CR60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41551-022-00964-5","volume":"7","author":"MT Spang","year":"2023","unstructured":"Spang, M. T. et al. Intravascularly infused extracellular matrix as a biomaterial for targeting and treating inflamed tissues. Nat. Biomed. Eng. 7, 94\u2013109 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"71843_CR61","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/nmat4956","volume":"16","author":"M Montgomery","year":"2017","unstructured":"Montgomery, M. et al. Flexible shape-memory scaffold for minimally invasive delivery of functional tissues. Nat. Mater. 16, 1038\u20131046 (2017).","journal-title":"Nat. Mater."},{"key":"71843_CR62","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.celbio.2025.100152","volume":"1","author":"K Huang","year":"2025","unstructured":"Huang, K. et al. Immunomodulatory microneedle patch for cardiac repair in rodent and porcine models of myocardial infarction. Cell Biomater. 1, 100152 (2025).","journal-title":"Cell Biomater."},{"key":"71843_CR63","doi-asserted-by":"publisher","first-page":"e0122377","DOI":"10.1371\/journal.pone.0122377","volume":"10","author":"R Blazquez","year":"2015","unstructured":"Blazquez, R. et al. Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis. PLoS One 10, e0122377 (2015).","journal-title":"PLoS One"},{"key":"71843_CR64","first-page":"571","volume":"40","author":"J Yao","year":"2024","unstructured":"Yao, J. et al. An infusible biologically active adhesive for chemotherapy-related heart failure in elderly rats. Bioact. Mater. 40, 571\u2013581 (2024).","journal-title":"Bioact. Mater."},{"key":"71843_CR65","doi-asserted-by":"publisher","first-page":"e0149001","DOI":"10.1371\/journal.pone.0149001","volume":"11","author":"R Bl\u00e1zquez","year":"2016","unstructured":"Bl\u00e1zquez, R. et al. Intrapericardial delivery of cardiosphere-derived cells: an immunological study in a clinically relevant large animal model. PLoS One 11, e0149001 (2016).","journal-title":"PLoS One"},{"key":"71843_CR66","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacbts.2017.06.003","volume":"2","author":"JR Garcia","year":"2017","unstructured":"Garcia, J. R. et al. A minimally invasive, translational method to deliver hydrogels to the heart through the pericardial space. JACC Basic Transl. Sci. 2, 601\u2013609 (2017).","journal-title":"JACC Basic Transl. Sci."},{"key":"71843_CR67","doi-asserted-by":"publisher","first-page":"16234","DOI":"10.1021\/acsnano.2c05168","volume":"16","author":"C Yu","year":"2022","unstructured":"Yu, C. et al. An intrapericardial injectable hydrogel patch for mechanical\u2013electrical coupling with infarcted myocardium. ACS Nano 16, 16234\u201316248 (2022).","journal-title":"ACS Nano"},{"key":"71843_CR68","doi-asserted-by":"publisher","first-page":"2004377","DOI":"10.1002\/adfm.202004377","volume":"31","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Injection of ROS-responsive hydrogel loaded with basic fibroblast growth factor into the pericardial cavity for heart repair. Adv. Funct. Mater. 31, 2004377 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"71843_CR69","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1161\/CIRCRESAHA.122.321384","volume":"131","author":"D Zhu","year":"2022","unstructured":"Zhu, D. et al. Intrapericardial exosome therapy dampens cardiac injury via activating Foxo3. Circ. Res. 131, e135\u2013e150 (2022).","journal-title":"Circ. Res."},{"key":"71843_CR70","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/eurheartj\/ehad114","volume":"44","author":"D Zhu","year":"2023","unstructured":"Zhu, D. et al. Intrapericardial long non-coding RNA\u2013Tcf21 antisense RNA inducing demethylation administration promotes cardiac repair. Eur. Heart J. 44, 1748\u20131760 (2023).","journal-title":"Eur. Heart J."},{"key":"71843_CR71","doi-asserted-by":"publisher","first-page":"2302686","DOI":"10.1002\/adma.202302686","volume":"36","author":"L Luo","year":"2024","unstructured":"Luo, L. et al. Pericardial delivery of SDF-1\u03b1 puerarin hydrogel promotes heart repair and electrical coupling. Adv. Mater. 36, 2302686 (2024).","journal-title":"Adv. Mater."},{"key":"71843_CR72","doi-asserted-by":"publisher","first-page":"131581","DOI":"10.1016\/j.cej.2021.131581","volume":"427","author":"J Li","year":"2022","unstructured":"Li, J. et al. Intrapericardial hydrogel injection generates high cell retention and augments therapeutic effects of mesenchymal stem cells in myocardial infarction. Chem. Eng. J. 427, 131581 (2022).","journal-title":"Chem. Eng. J."},{"key":"71843_CR73","doi-asserted-by":"publisher","first-page":"015025","DOI":"10.1088\/1758-5090\/ad8e87","volume":"17","author":"\u015e Ar\u0131c\u0131","year":"2024","unstructured":"Ar\u0131c\u0131, \u015e, Kamali, A. R. & Ege, D. CMC\/Gel\/GO 3D-printed cardiac patches: GO and CMC improve flexibility and promote H9C2 cell proliferation, while EDC\/NHS enhances stability. Biofabrication 17, 015025 (2024).","journal-title":"Biofabrication"},{"key":"71843_CR74","doi-asserted-by":"publisher","first-page":"100391","DOI":"10.1016\/j.mtbio.2022.100391","volume":"16","author":"IL Chin","year":"2022","unstructured":"Chin, I. L. et al. Mechanosensation mediates volume adaptation of cardiac cells and spheroids in 3D. Mater. Today Bio 16, 100391 (2022).","journal-title":"Mater. Today Bio"},{"key":"71843_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/01.TP.0000148733.57977.FD","volume":"79","author":"M Zhu","year":"2005","unstructured":"Zhu, M. et al. Inhibition of xenogeneic response in porcine endothelium using RNA interference. Transplantation 79, 289\u2013296 (2005).","journal-title":"Transplantation"},{"key":"71843_CR76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.stem.2017.06.005","volume":"21","author":"G Gintant","year":"2017","unstructured":"Gintant, G., Fermini, B., Stockbridge, N. & Strauss, D. The evolving roles of human iPSC-derived cardiomyocytes in drug safety and discovery. Cell Stem Cell 21, 14\u201317 (2017).","journal-title":"Cell Stem Cell"},{"key":"71843_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/stmcls\/sxaf005","volume":"43","author":"S Gulberk Ozcebe","year":"2025","unstructured":"Gulberk Ozcebe, S., Tristan, M. & Zorlutuna, P. Adult human heart extracellular matrix improves human iPSC-CM function via mitochondrial and metabolic maturation. Stem Cells 43, sxaf005 (2025).","journal-title":"Stem Cells"},{"key":"71843_CR78","first-page":"39","volume":"16","author":"MAC Lima","year":"2022","unstructured":"Lima, M. A. C. et al. Cardiotoxicity in cancer patients treated with chemotherapy: a systematic review. Int. J. Health Sci. 16, 39\u201346 (2022).","journal-title":"Int. J. Health Sci."},{"key":"71843_CR79","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/0277-5379(89)90135-1","volume":"25","author":"SS Bielack","year":"1989","unstructured":"Bielack, S. S., Erttmann, R., Winkler, K. & Landbeck, G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur. J. Cancer Clin. Oncol. 25, 873\u2013882 (1989).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"71843_CR80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu, K., GA, V., BT, P. & Arunachalam, S. Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. Eur. J. Pharmacol. 818, 241\u2013253 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"71843_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04715-1","volume":"21","author":"P Tai","year":"2023","unstructured":"Tai, P. et al. WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis. J. Transl. Med. 21, 823 (2023).","journal-title":"J. Transl. Med."},{"key":"71843_CR82","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41418-019-0372-z","volume":"27","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. Cell Death Differ. 27, 540\u2013555 (2020).","journal-title":"Cell Death Differ."},{"key":"71843_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203505","volume":"9","author":"M Fan","year":"2022","unstructured":"Fan, M. et al. Decoy exosomes offer protection against chemotherapy-induced toxicity. Adv. Sci. 9, e2203505 (2022).","journal-title":"Adv. Sci."},{"key":"71843_CR84","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1078155219877931","volume":"26","author":"HS Al-Malky","year":"2020","unstructured":"Al-Malky, H. S., Al Harthi, S. E. & Osman, A. M. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J. Oncol. Pharm. Pract. 26, 434\u2013444 (2020).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"71843_CR85","doi-asserted-by":"publisher","first-page":"113910","DOI":"10.1016\/j.ejmech.2021.113910","volume":"227","author":"M Li","year":"2022","unstructured":"Li, M. et al. The nano delivery systems and applications of mRNA. Eur. J. Med. Chem. 227, 113910 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"71843_CR86","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"71843_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 8, 156 (2023).","journal-title":"NPJ Vaccines"},{"key":"71843_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020402","volume":"10","author":"J Li","year":"2021","unstructured":"Li, J. et al. All roads lead to rome (the heart): cell retention and outcomes from various delivery routes of cell therapy products to the heart. J. Am. Heart Assoc. 10, e020402 (2021).","journal-title":"J. Am. Heart Assoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71843-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:02:56Z","timestamp":1784854976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71843-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71843"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71843-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7196"}}